Welldoc, a Columbia, Maryland-based digital health company, has gained an additional FDA approval for its BlueStar diabetes management solution.
This most recent approval covers BlueStar’s Insulin Adjustment Program (IAP) feature, which automatically makes needed insulin dose adjustments for adult patients with type 2 diabetes. According to Mansur Shomali, MD, Welldoc’s chief medical officer, this feature helps patients receive the care they need as soon as they need it and can lead to more productive conversations with physicians.
“With BlueStar's IAP, a provider prescribes a safe starting dose of insulin for his or her patient, and BlueStar does the rest,” Shomali said in a prepared statement. “The patient no longer has to wait to talk to his or her provider to adjust the insulin. The next time the patient meets with his or her health care provider, the insulin dose has been optimized and they can spend their visit focusing on other important elements of the patient's care.”
Michael has more than 16 years of experience as a professional writer and editor. He has written at length about cardiology, radiology, artificial intelligence and other key healthcare topics.